Biogen expands executive team at spin-out Bioverativ

US biotech major Biogen (Nasdaq: BIIB) has named two members to the executive management team of Bioverativ, its planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.

Rogerio Vivaldi, will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John Greene will take the post of executive vice president and chief financial officer of Bioverativ. The spin-off of Bioverativ is on track to be completed in early 2017.

“Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community,” remarked George Scangos, chief executive of Biogen, adding: “Rogerio and John will be instrumental players in that success, alongside the rest of the executive team.”